Knee Osteoarthritis
Conditions
Interventions
After the arthroscopic bone marrow stimulation technique is performed on the articular cartilage defect, a suspension of bone marrow fluid-derived m-MSCs from the subject is injected in the presence o
Sponsors
Kamei Naosuke
Flying Cell Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients whose age is between 20 and 80 years old at the time of obtaining consent 2) Patients whose written consent has been obtained 3) Patients who have been diagnosed with kneeosteoarthritis 4) Patients with Kellgren-Lawrence classification grade 2 or 3 osteoarthritis on X-ray examination 5) Patients whose articular cartilage damage is limited to the medial condyle or lateral condyle 6) Patients who have received conservative treatment, including exercise therapy, for at least 3 months from the time of enrollment 7) Patients with clinical symptoms of pain in the knee
Exclusion criteria
Exclusion criteria: 1) Patients who have undergone reconstruction of the anterior cruciate ligament and/or posterior cruciate ligament within 2 months of enrollment in the study 2) Patients scheduled for treatment of meniscus injury or patients who have undergone surgery for meniscus injury within 6 months of enrollment in the study 3) Patients with knee deformity inward or outward more than 10 degrees from the normal value (FTA 175 degrees) 4) Patients with implanted medical devices that may be affected by magnetic fields 5) Patients with malignant tumors, suspected malignant tumors, or with a history of malignant tumors within 5 years 6) Patients who are pregnant or may be pregnant, who are breast-feeding, or who wish to become pregnant during this study 7) Patients with psychiatric disorders 8) Patients with a history of hypersensitivity to ferucarbotran components or iron injection 9) Patients with iron overload such as hemochromatosis 10) Patients with active bleeding 11) Patients with allergy to animals (bovine or porcine) 12) Patients with hypersensitivity to gentamicin or amphotericin B, and patients with a history of hypersensitivity to aminoglycoside antibiotics 13) Patients who are positive for beef allergy test 14) Patients who are positive for any of the following tests; HBs antigen test, HCV antibody test, or HIV antibody test 15) Other patients who are judged by the investigator or sub-investigator to be inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of adverse events (%) and incidence rate of defects (%) | — |
Secondary
| Measure | Time frame |
|---|---|
| Completion rate of procedures using investigational device | — |
Contacts
Public ContactNaosuke Kamei
Hiroshima University Hospital
Outcome results
None listed